These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29403263)

  • 1. Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent
    Navalkele BD; Chopra T
    Biologics; 2018; 12():11-21. PubMed ID: 29403263
    [No Abstract]   [Full Text] [Related]  

  • 2. Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.
    Kufel WD; Devanathan AS; Marx AH; Weber DJ; Daniels LM
    Pharmacotherapy; 2017 Oct; 37(10):1298-1308. PubMed ID: 28730660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence.
    Deeks ED
    Drugs; 2017 Oct; 77(15):1657-1663. PubMed ID: 28865041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review.
    Thandavaram A; Channar A; Purohit A; Shrestha B; Patel D; Shah H; Hanna K; Kaur H; Alazzeh MS; Mohammed L
    Cureus; 2022 Aug; 14(8):e27979. PubMed ID: 36120235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
    Posteraro B; Pea F; Masucci L; Posteraro P; Sanguinetti M
    Expert Opin Biol Ther; 2018 Apr; 18(4):469-476. PubMed ID: 29534621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
    Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
    Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preclinical and clinical properties of Bezlotoxumab (ZINPLAVA
    Kinoshita K
    Nihon Yakurigaku Zasshi; 2018; 152(1):39-50. PubMed ID: 29998951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.
    Villafuerte Gálvez JA; Kelly CP
    Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):611-622. PubMed ID: 28636484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
    Wilcox MH; Gerding DN; Poxton IR; Kelly C; Nathan R; Birch T; Cornely OA; Rahav G; Bouza E; Lee C; Jenkin G; Jensen W; Kim YS; Yoshida J; Gabryelski L; Pedley A; Eves K; Tipping R; Guris D; Kartsonis N; Dorr MB;
    N Engl J Med; 2017 Jan; 376(4):305-317. PubMed ID: 28121498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.
    Mikamo H; Aoyama N; Sawata M; Fujimoto G; Dorr MB; Yoshinari T
    J Infect Chemother; 2018 Feb; 24(2):123-129. PubMed ID: 29097028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection.
    Prabhu VS; Dubberke ER; Dorr MB; Elbasha E; Cossrow N; Jiang Y; Marcella S
    Clin Infect Dis; 2018 Jan; 66(3):355-362. PubMed ID: 29106516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies.
    Giacobbe DR; Dettori S; Di Bella S; Vena A; Granata G; Luzzati R; Petrosillo N; Bassetti M
    Infect Dis Ther; 2020 Sep; 9(3):481-494. PubMed ID: 32632582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection.
    Birch T; Golan Y; Rizzardini G; Jensen E; Gabryelski L; Guris D; Dorr MB
    J Antimicrob Chemother; 2018 Sep; 73(9):2524-2528. PubMed ID: 29788418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?
    Chapin RW; Lee T; McCoy C; Alonso CD; Mahoney MV
    Ann Pharmacother; 2017 Sep; 51(9):804-810. PubMed ID: 28480750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
    Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
    Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
    Bouza E; Cornely OA; Ramos-Martinez A; Plesniak R; Ellison MC; Hanson ME; Dorr MB
    Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1933-1939. PubMed ID: 32504314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Association Reveals Protection against Recurrence of
    Shen J; Mehrotra DV; Dorr MB; Zeng Z; Li J; Xu X; Nickle D; Holzinger ER; Chhibber A; Wilcox MH; Blanchard RL; Shaw PM
    mSphere; 2020 May; 5(3):. PubMed ID: 32376702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.
    Salavert M; Cobo J; Pascual Á; Aragón B; Maratia S; Jiang Y; Aceituno S; Grau S
    Adv Ther; 2018 Nov; 35(11):1920-1934. PubMed ID: 30328061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Bezlotoxumab for Prevention of Recurrent
    Johnson TM; Howard AH; Miller MA; Allen LL; Huang M; Molina KC; Bajrovic V
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab294. PubMed ID: 34262988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes.
    Johnson S; Citron DM; Gerding DN; Wilcox MH; Goldstein EJC; Sambol SP; Best EL; Eves K; Jensen E; Dorr MB
    Clin Infect Dis; 2021 Nov; 73(9):e2616-e2624. PubMed ID: 32735653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.